The LEF1 (Lymphoid Enhancer-Binding Factor 1) antibody is a key tool for studying the role of LEF1. a transcription factor in the Wnt/β-catenin signaling pathway. LEF1 belongs to the TCF/LEF family of proteins and regulates gene expression by interacting with β-catenin to activate target genes involved in cell proliferation, differentiation, and embryonic development. It plays critical roles in immune system regulation, particularly in T-cell development, and is implicated in cancer progression, including leukemia, colorectal carcinoma, and breast cancer. Dysregulation of LEF1 is associated with tumor invasiveness, epithelial-mesenchymal transition (EMT), and therapy resistance.
LEF1 antibodies are widely used in research to detect protein expression and localization via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. These antibodies help identify LEF1 overexpression or nuclear accumulation in cancer tissues, serving as potential diagnostic or prognostic biomarkers. They also aid in studying LEF1's interaction with β-catenin and DNA, as well as its regulatory effects on downstream targets (e.g., c-MYC, Cyclin D1).
Available as monoclonal or polyclonal variants, LEF1 antibodies are typically validated for specificity against human, mouse, or rat samples. Researchers must optimize experimental conditions due to potential cross-reactivity with other TCF/LEF family members. Their applications extend to developmental biology, oncology, and drug discovery, particularly in therapies targeting Wnt pathway abnormalities.